Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma - a Randomized Controlled Trial

Trial Profile

Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma - a Randomized Controlled Trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Sorafenib (Primary) ; Vitamin K
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Apr 2016 Primary endpoint has been met; (Overall Survival), according to the results published.
    • 17 Apr 2016 Status changed from recruiting to active, no longer recruiting, according to the results published.
    • 17 Apr 2016 Efficacy and safety results (n=60) presented at The International Liver Congress™ 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top